Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$10000.0.

  • Akebia Therapeutics' Non Operating Income rose 4117.65% to -$10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $230000.0, marking a year-over-year decrease of 6700.14%. This contributed to the annual value of $94000.0 for FY2024, which is 8940.25% down from last year.
  • Per Akebia Therapeutics' latest filing, its Non Operating Income stood at -$10000.0 for Q3 2025, which was up 4117.65% from -$28000.0 recorded in Q2 2025.
  • Akebia Therapeutics' Non Operating Income's 5-year high stood at $1.3 million during Q2 2021, with a 5-year trough of -$43000.0 in Q3 2023.
  • For the 5-year period, Akebia Therapeutics' Non Operating Income averaged around $353421.1, with its median value being $213000.0 (2025).
  • In the last 5 years, Akebia Therapeutics' Non Operating Income soared by 60434.78% in 2022 and then tumbled by 29000.0% in 2024.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Non Operating Income stood at $560000.0 in 2021, then dropped by 22.5% to $434000.0 in 2022, then surged by 51.61% to $658000.0 in 2023, then crashed by 91.64% to $55000.0 in 2024, then tumbled by 118.18% to -$10000.0 in 2025.
  • Its last three reported values are -$10000.0 in Q3 2025, -$28000.0 for Q2 2025, and $213000.0 during Q1 2025.